Braeden Freitas
A5080018981- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
The University of Texas Southwestern Medical Center
2023-2024
Abstract Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients has been difficult to capture laboratory models. Here, we present preclinical system that recapitulates acquired cross-resistance, developed from 51 patient-derived xenograft (PDX) Each model was tested vivo against three clinical regimens: cisplatin plus etoposide, olaparib temozolomide, and topotecan. These...
ABSTRACT Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients has been difficult to capture laboratory models. Here we present pre-clinical system that recapitulates acquired SCLC, developed from 51 patient-derived xenografts (PDXs). Each model was tested for vivo sensitivity three clinical regimens: cisplatin plus etoposide, olaparib temozolomide, and topotecan. These...
<p>MYC paralog copy number and ecDNA status in SCLC cell lines, PDX models biopsy samples derived before treatment or after relapse.</p>
<p>Comparison gene expression and H3K27ac between MGH1518 serial models</p>
<p>Genomic analysis of chromosome 17 focal amplification in MGH1531-5BX and ecDNA junction mutations MGH1518-3A.</p>
<p>Comparison of chemotherapy regimen delta-AUC and comparison average by PDX source.</p>
<p>Method to compare ecMYC level with resistance drug-induced DNA damage.</p>
<p>Acquired ecMYCN amplification in MGH1578 serial models and lineage oncogene expression compared with ecDNA status across the PDX panel.</p>
<p>Reconstruction of ecDNAs containing MYC paralogs and MYCL FISH in MGH1501-1A metaphase chromosomes.</p>
<p>Levels of ecMYC in untreated and treated MGH1518-3A xenografts</p>
<p>Calculation of delta-AUC and comparison EC with EP in PDX models.</p>
<p>MYC paralog amplifications that were detected or omitted by segmented copy number analysis, and patient survival compared with ecDNA status of PDX models.</p>
<p>Untreated PDX growth curves.</p>
<p>Frequency of amplified oncogenes across PDX panel, similarity ecMYC/L/N structures, and regression analysis average drug response versus MYC paralog copy number, expression amplicon type.</p>
<p>Reconstruction of ecDNAs that do not contain MYC paralogs.</p>
<p>Genomic analysis of chromosome 8 focal amplification in MGH1518-3A</p>
<div>Abstract<p>Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients has been difficult to capture laboratory models. Here, we present preclinical system that recapitulates acquired cross-resistance, developed from 51 patient-derived xenograft (PDX) Each model was tested <i>in vivo</i> against three clinical regimens: cisplatin plus etoposide,...
<p>Reconstruction of ecDNAs containing MYC paralogs and MYCL FISH in MGH1501-1A metaphase chromosomes.</p>
<p>MYC paralog copy number and ecDNA status in SCLC cell lines, PDX models biopsy samples derived before treatment or after relapse.</p>
<p>Untreated PDX growth curves.</p>
<p>Frequency of amplified oncogenes across PDX panel, similarity ecMYC/L/N structures, and regression analysis average drug response versus MYC paralog copy number, expression amplicon type.</p>
<p>Genomic analysis of chromosome 17 focal amplification in MGH1531-5BX and ecDNA junction mutations MGH1518-3A.</p>
<p>MYC paralog amplifications that were detected or omitted by segmented copy number analysis, and patient survival compared with ecDNA status of PDX models.</p>
<p>Comparison of chemotherapy regimen delta-AUC and comparison average by PDX source.</p>